GlassScriptPhysician profile
David A Jawahar
NPI 1306828330
$9,180.15
in general payments reported to CMS, 2019-2025
37 companies · $2,267 in 2025
The $2,267 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $688 · 2021: $1,256 · 2022: $925 · 2023: $1,711 · 2024: $1,659 · 2025: $2,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,444 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,443.58 |
| Education | $194.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,519.34 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,442.97 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $714.84 | 2019-2025 | Dupixent |
| Genzyme Corporation | $532.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.56 | 2019-2024 | Ofev |
| Genentech USA, INC. | $328.57 | 2019-2024 | Xolair |
| Mallinckrodt Hospital Products INC. | $320.47 | 2021-2024 | Acthar |
| Jazz Pharmaceuticals INC. | $275.82 | 2019-2024 | |
| Pulmonx Corporation | $264.72 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Mylan Specialty L.P. | $264.71 | 2020-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $216.12 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $193.94 | 2019-2021 | |
| Insmed, INC. | $149.42 | 2020-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $147.23 | 2021-2023 | Glassia, Hyqvia |
| Bayer Healthcare Pharmaceuticals INC. | $141.52 | 2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $128.64 | 2025 | Yupelri |
| Philips North America LLC | $104.71 | 2019-2025 | Vest Therapy Und, Patient Interface Software |
| Sanofi-Aventis U.S. LLC | $89.99 | 2024 | |
| Grifols USA, LLC | $83.81 | 2024-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $74.31 | 2020-2023 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $73.31 | 2024-2025 | Lumryz |
| Resmed Corp | $64.83 | 2019-2025 | |
| Amgen INC. | $64.73 | 2023-2025 | Tezspire |
| Verona Pharma, INC. | $60.79 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $53.92 | 2023-2024 | Keytruda, Recarbrio, Zerbaxa |
| Axsome Therapeutics, INC. | $52.46 | 2023-2024 | Sunosi |
| Covis Pharma Gmbh | $51.84 | 2022-2023 | |
| Greer Laboratories, INC. | $46.57 | 2023-2025 | Oralair |
| Electromed, INC. | $45.52 | 2024 | Smartvest |
| Tactile Systems Technology INC | $40.27 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| United Therapeutics Corporation | $37.75 | 2021 | |
| Ani Pharmaceuticals, INC. | $34.09 | 2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $29.00 | 2025 | Zepbound |
| Abbvie INC. | $24.43 | 2022 | |
| Cmp Pharma, INC. | $23.84 | 2025 | Tadliq, Liqrev, Norliqva |
| Sunovion Pharmaceuticals INC. | $12.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jawahar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.